Delving into the Latest Updates on [18F]F-AraG with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine, VisAcT

+ [4]

Target

DCK x DGUOK

Mechanism

DCK inhibitors(Deoxycytidine kinase inhibitors), DGUOK inhibitors(deoxyguanosine kinase inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication

Locally Advanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid NeoplasmNon-Hodgkin Lymphoma+ [4]

Inactive Indication

COVID-19HIV InfectionsSquamous Cell Carcinoma of Head and Neck+ [1]

Originator Organization

Stanford University

Active Organization

CellSight Technologies, Inc.

Stanford University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H12FN5O4

InChIKeyUXUZARPLRQRNNX-YXAALHNKSA-N

CAS Registry1268848-88-9

The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor.
This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.

Start Date01 Jul 2024

Sponsor / Collaborator

Stichting Onderzoek Cancer Center Amsterdam

[+1]

NCT06107374 / RecruitingPhase 2

Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy

This pilot study uses [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to quantify the change in [18F]F AraG PET signal before and while on CkIT therapy and to correlate this change in [18F]F AraG PET signal with radiographic response.
To explore these objectives, eligible subjects will undergo pre- and on - CkIT treatment [18F]F AraG PET/CT scans, and will be followed up for 12 months for assessment of radiographic and clinical outcomes. This study is a single-site, open label, non randomized, single arm pilot trial. Patients and care providers will not be blinded to any part of the study.

Start Date01 Nov 2023

Sponsor / Collaborator

CellSight Technologies, Inc.

100 Clinical Results associated with [18F]F-AraG

Login to view more data

100 Translational Medicine associated with [18F]F-AraG

Login to view more data

100 Patents (Medical) associated with [18F]F-AraG

Login to view more data

466

Literatures (Medical) associated with [18F]F-AraG

18 Oct 2024·Journal of Alzheimer's Disease

Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer’s Disease: An Overview of the Current State of the Art of Research

Review

Author: Liguori, Claudio ; Mercuri, Nicola Biagio ; Schillaci, Orazio ; Chiaravalloti, Agostino ; Triumbari, Elizabeth Katherine Anna

The integration of positron emission tomography/computed tomography (PET/CT) has revolutionized the landscape of Alzheimer’s disease (AD) research and therapeutic interventions. By combining structural and functional imaging, PET/CT provides a comprehensive understanding of disease pathology and response to treatment assessment. PET/CT, particularly with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), facilitates the visualization of glucose metabolism in the brain, enabling early diagnosis, staging, and monitoring of neurodegenerative disease progression. The advent of amyloid and tau PET imaging has further propelled the field forward, offering invaluable tools for tracking pathological hallmarks, assessing treatment response, and predicting clinical outcomes. While some therapeutic interventions targeting amyloid plaque load showed promising results with the reduction of cerebral amyloid accumulation over time, others failed to demonstrate a significant impact of anti-amyloid agents for reducing the amyloid plaques burden in AD brains. Tau PET imaging has conversely fueled the advent of disease-modifying therapeutic strategies in AD by supporting the assessment of neurofibrillary tangles of tau pathology deposition over time. Looking ahead, PET imaging holds immense promise for studying additional targets such as neuroinflammation, cholinergic deficit, and synaptic dysfunction. Advances in radiotracer development, dedicated brain PET/CT scanners, and Artificial Intelligence-powered software are poised to enhance the quality, sensitivity, and diagnostic power of molecular neuroimaging. Consequently, PET/CT remains at the forefront of AD research, offering unparalleled opportunities for unravelling the complexities of the disease and advancing therapeutic interventions, although it is not yet enough alone to allow patients’ recruitment in therapeutic clinical trials.

01 Oct 2024·PET Clinics

2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas

Review

Author: Bonnet, Christophe ; Hustinx, Roland ; Withofs, Nadia

The 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography combined with computed tomography (PET/CT) has contributed to outcome improvement of patients with lymphoma. The use of [¹⁸F]FDG PET/CT for staging and response assessment is successfully applied both in routine clinical practice and in clinical trials. The challenges lie in enhancing the outcomes of lymphoma patients, particularly those with advanced or refractory/relapsed disease, and to minimize the long-term toxicity associated with treatments, including radiation therapy. The objective of this review article is to present contemporary data on the use of [¹⁸F]FDG PET/CT for treatment assessment of aggressive lymphomas.

01 Oct 2024·Molecular Imaging and Biology

A Feasibility Study of [18F]F-AraG Positron Emission Tomography (PET) for Cardiac Imaging–Myocardial Viability in Ischemia–Reperfusion Injury Model

Article

Author: Seo, Youngho ; Levi, Jelena ; Lee, Randall J ; Packiasamy, Juliet ; VanBrocklin, Henry F ; Huynh, Lyna ; Fang, Qizhi ; Blecha, Joseph ; Huynh, Tony L ; Shrestha, Uttam M ; Chae, Hee-Don

PURPOSEMyocardial infarction (MI) with subsequent inflammation is one of the most common heart conditions leading to progressive tissue damage. A reliable imaging marker to assess tissue viability after MI would help determine the risks and benefits of any intervention. In this study, we investigate whether a new mitochondria-targeted imaging agent, ¹⁸F-labeled 2'-deoxy-2'-¹⁸F-fluoro-9-β-d-arabinofuranosylguanine ([¹⁸F]F-AraG), a positron emission tomography (PET) agent developed for imaging activated T cells, is suitable for cardiac imaging and to test the myocardial viability after MI.PROCEDURETo test whether the myocardial [¹⁸F]-F-AraG signal is coming from cardiomyocytes or immune infiltrates, we compared cardiac signal in wild-type (WT) mice with that of T cell deficient Rag1 knockout (Rag1 KO) mice. We assessed the effect of dietary nucleotides on myocardial [¹⁸F]F-AraG uptake in normal heart by comparing [¹⁸F]F-AraG signals between mice fed with purified diet and those fed with purified diet supplemented with nucleotides. The myocardial viability was investigated in rodent model by imaging rat with [¹⁸F]F-AraG and 2-deoxy-2[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) before and after MI. All PET signals were quantified in terms of the percent injected dose per cc (%ID/cc). We also explored [¹⁸F]FDG signal variability and potential T cell infiltration into fibrotic area in the affected myocardium with H&E analysis.RESULTSThe difference in %ID/cc for Rag1 KO and WT mice was not significant (p = ns) indicating that the [¹⁸F]F-AraG signal in the myocardium was primarily coming from cardiomyocytes. No difference in myocardial uptake was observed between [¹⁸F]F-AraG signals in mice fed with purified diet and with purified diet supplemented with nucleotides (p = ns). The [¹⁸F]FDG signals showed wider variability at different time points. Noticeable [¹⁸F]F-AraG signals were observed in the affected MI regions. There were T cells in the fibrotic area in the H&E analysis, but they did not constitute the predominant infiltrates.CONCLUSIONSOur preliminary preclinical data show that [¹⁸F]F-AraG accumulates in cardiomyocytes indicating that it may be suitable for cardiac imaging and to evaluate the myocardial viability after MI.

100 Deals associated with [18F]F-AraG

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	US	CellSight Technologies, Inc.	01 Nov 2023
Advanced Malignant Solid Neoplasm	Phase 2	US	CellSight Technologies, Inc.	01 Mar 2022
Advanced Malignant Solid Neoplasm	Phase 2	US	Stanford University	01 Mar 2022
Non-Hodgkin Lymphoma	Phase 2	US	CellSight Technologies, Inc.	28 Sep 2021
Non-Hodgkin Lymphoma	Phase 2	US	Stanford University	28 Sep 2021
Advanced Lung Non-Small Cell Carcinoma	Phase 2	US	CellSight Technologies, Inc.	15 Apr 2021
Urothelial Carcinoma of the Urinary Bladder	Phase 2	US	CellSight Technologies, Inc.	07 Mar 2017
Bladder Cancer	Phase 2	-	Stanford University	-
Non-Small Cell Lung Cancer	Phase 2	-	Stanford University	-
Head and Neck Neoplasms	Phase 1	-	Stanford University	-